Why is it so Hard to Find New Medicines for Alzheimer’s disease?

During November, we recognize the impact of caregiving and honor the more than 15 million Americans caring for someone with Alzheimer's Disease. President Bill Clinton named the week of Thanksgiving as a time to honor caregivers in 1997, and that has since expanded to National Family Caregivers Month. November is also National Alzheimer's Disease Awareness Month (NADAM). Signed into proclamation by President Ronald Reagan in 1983.

NADAM remains a great opportunity to raise public concern of the disease and is a good time for seniors and their caregivers to learn about the condition. Whether you have the diagnosis, know or take care of someone who suffers from the disease, understanding Alzheimer's and other related dementias is critical to maintaining your health or that of your loved one.

The Alzheimer's Association reports that more than 5 million Americans are living with Alzheimer's disease, including an estimated 200,000 under the age of 65. By 2050, that number is expected to triple, affecting 16 million Americans. Alzheimer's disease is the only condition among the nation's leading causes of death that cannot be fully prevented, slowed, or cured.

You can learn more about innovations in Alzheimer’s disease research with Dr. Richard Mohs by taking part in the Alzheimer's Association, Rhode Island Chapter's annual Brian R. Ott M.D. Research Symposium on Thursday November 8, 2018 at the Radisson Hotel Providence Airport in Warwick, RI. Reception and cash bar open at 5:30pm with the presentation beginning at 6:00pm.

This year's guest speaker, Richard Mohs, PhD, will focus on “Why it is so Hard to Find New Medicines for Alzheimer’s disease.” Richard C. Mohs, PhD is the Chief Scientific Officer for the Global Alzheimer’s Platform (GAP) Foundation. In addition to his work for the GAP Foundation, Dr. Mohs serves as a consultant to Agenebio, a Baltimore-based company developing an SV2A antagonist for treatment of mild cognitive impairment. He also serves as a member of the Board of Governors for the Alzheimer’s Drug Discovery Foundation in New York, a member of the Board of Directors for Cog State, Ltd, based in Melbourne, Australia, and as Senior Associate Editor for Alzheimer’s and Dementia, the journal of the Alzheimer’s Association.

The symposium is free to attend and open to the public, but pre-registration is required. Contact the Alzheimer's Association, Rhode Island Chapter's office to pre-register at 1-800-272-3900 or visit communityresourcefinder.org.

This activity is pending approval by the Northeast Multi-State Division (NE-MSD) for Continuation Education Credits. Northeast Multistate Division (NE-MSD) is accredited as an approver of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

This activity is pending approval by NASW RI for Continuing Education Credits.